Bayer gets FDA priority review for blood cancer drug

FRANKFURT, Germany (Reuters) - German drugmaker Bayer won the U.S. Food and Drug Administration's priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.